Patent application number | Description | Published |
20080199424 | MART-1 T CELL RECEPTORS - T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma. | 08-21-2008 |
20080300211 | MICRORNA INHIBITION FOR THE TREATMENT OF INFLAMMATION AND MYELOPROLIFERATIVE DISORDERS - The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1α, Sla, Cepbβ, and Bach1, and the like. | 12-04-2008 |
20090203136 | MODULATING IMMUNE SYSTEM DEVELOPMENT AND FUNCTION THROUGH MICRORNA MIR-146 - The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed. | 08-13-2009 |
20100120122 | TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 05-13-2010 |
20100120140 | TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 05-13-2010 |
20100203630 | IN VITRO HUMAN B LYMPHOPOIESIS CULTURE SYSTEM - The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs). | 08-12-2010 |
20100267146 | METHOD FOR EXPRESSION OF SMALL ANTIVIRAL RNA MOLECULES WITH REDUCED CYTOTOXICITY WITHIN A CELL - In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. | 10-21-2010 |
20110014659 | ISOLATION OF UNKNOWN REARRANGED T-CELL RECEPTORS FROM SINGLE CELLS - Disclosed herein are methods and materials for isolating and identifying T cell receptors from single cells. In some embodiments, genomic DNA from a single T cell is isolated using whole genome amplification (WGA). A series of PCR reactions is carried out to enrich the genomic template for sequences encoding the TCR alpha and beta chains, and then to isolate the sequences encoding the TCR alpha and beta chains. | 01-20-2011 |
20110059531 | METHOD FOR EXPRESSION OF SMALL RNA MOLECULES WITHIN A CELL - The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated. | 03-10-2011 |
20110212530 | METHOD OF TARGETED GENE DELIVERY USING VIRAL VECTORS - Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency. | 09-01-2011 |
20110258716 | MODULATING IMMUNE SYSTEM DEVELOPMENT AND FUNCTION THROUGH MICRORNA MIR-146 - The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed. | 10-20-2011 |
20120064122 | TREATMENT OF AUTOIMMUNE INFLAMMATION USING MIR-155 - The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T | 03-15-2012 |
20120065245 | REGULATION OF HEMATOPOIETIC STEM CELL FUNCTIONS THROUGH MICRORNAS - The present disclosure relates to regulation of functions of hematopoietic stem cells (HSCs) by delivering of miRNAs, including miR-125b, miR-126, and miR-155, to HSCs. For example, in some embodiments, blood output in a mammal can be increased by administering miR-125b, miR-126, and/or miR-155 oligonucleotides. Also disclosed are methods for promoting hematopoietic stem cell engraftment and method for treating a myeloproliferative disorder. | 03-15-2012 |
20120070462 | Targeted Gene Delivery to Dendritic Cells - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 03-22-2012 |
20120121608 | USE OF SAM68 FOR MODULATING SIGNALING THROUGH THE TNF RECEPTOR - Sam68 plays a role in TNF-dependent signaling, including NF-kB signaling and extrinsic activation of apoptosis. In some embodiments, inhibitors of Sam68 are administered to inhibit TNF-dependent signaling, for example to inhibit NF-kB signaling or apoptosis in a patient in need. In some embodiments, functional Sam68 is administered to increase TNF-dependent signaling, for example to induce apoptosis in a patient in need. In some embodiments, methods are provided determining whether the TNF-dependent or TNF-independent branch of a signaling pathway is active in a cell or cells, or for drug screening applications. | 05-17-2012 |
20120196361 | MART-1 T CELL RECEPTORS - T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma. | 08-02-2012 |
20120232133 | DELIVERY OF PROTEINS USING ADENO-ASSOCIATED VIRUS (AAV) VECTORS - Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors. | 09-13-2012 |
20120322854 | REGULATION OF MACROPHAGE ACTIVATION USING MIR-125B - The present disclosure relates to regulation of macrophage activation by delivering of miRNAs, for example miR-125 | 12-20-2012 |
20130230554 | TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 09-05-2013 |
20130260453 | METHOD FOR EXPRESSION OF SMALL RNA MOLECULES WITHIN A CELL - The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated. | 10-03-2013 |
20130295615 | METHOD FOR EXPRESSION OF SMALL ANTIVIRAL RNA MOLECULES WITH REDUCED CYTOTOXICITY WITHIN A CELL - In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. | 11-07-2013 |
20130316366 | EXPRESSION OF SECRETED AND CELL-SURFACE POLYPEPTIDES - Some embodiments herein provide compositions and methods for expressing secreted and cell-surface-bound polypeptides in a single cell. In some embodiments, secreted and cell-surface polypeptide are produced from a single polynucleotide. The polynucleotide can comprise a sequence (or sequence encoding a polypeptide) that mediates separation of a membrane anchor from the polypeptide. In some embodiments, a desired ratio of secreted to surface-bound polypeptide is obtained by selecting a sequence that mediates a desired level of separation of the membrane anchor from the polypeptide. | 11-28-2013 |
20140127162 | REVERSIBLE GENE EXPRESSION - According to some embodiments herein, expression systems and methods for reversible gene expression are provided. In some embodiments, adeno-associated viral vectors encoding a gene product of interest and comprising a plurality of recombinase target sites are provided. In some embodiments, a source of recombinase is provided. In some embodiments, the gene product of interest is expressed, and the recombinase then induces recombination events between the recombinase target sites, thus reducing or eliminating expression of the gene product of interest. | 05-08-2014 |
20140212876 | TARGETING C-REL O-GLCNACYLATION AND USES THEREOF - Serine 350 has been identified as the site of O-GlycNAcylation of c-Rel. Methods are provided for identifying compositions capable of blocking c-Rel activation. The methods generally involve identifying compounds that inhibit O-GlcNAcylation of c-Rel at the serine 350 residue, thereby preventing c-Rel activation and production of c-Rel-dependent cytokines. | 07-31-2014 |
20140220049 | MICRORNA INHIBITION FOR THE TREATMENT OF INFLAMMATION AND MYELOPROLIFERATIVE DISORDERS - The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIFlα, Sla, Cepbβ, and Bach1, and the like. | 08-07-2014 |